Your browser doesn't support javascript.
loading
Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura.
Thomsen, Andreas Vinther; Al-Karagholi, Mohammad Al-Mahdi; Hougaard, Anders; Ostrowski, Sisse Rye; Pedersen, Ole Birger; Hansen, Thomas Folkmann; Ashina, Messoud.
Afiliação
  • Thomsen AV; Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
  • Al-Karagholi MA; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hougaard A; Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
  • Ostrowski SR; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Pedersen OB; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hansen TF; Department of Neurology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Ashina M; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Cephalalgia ; 44(3): 3331024241237247, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38501895
ABSTRACT
BACKGROUND/

HYPOTHESIS:

Experimental provocation studies have yielded important insights in migraine pathophysiology. Levcromakalim has been previously shown to induce migraine-like attacks with and without aura. In this study, we aim to further explore the migraine aura-inducing potential of levcromakalim.

METHODS:

In a double-blind, randomized, placebo-controlled cross-over study, 27 adult participants with migraine with aura received intravenous infusions of levcromakalim and saline. Headache, aura and associated symptoms were evaluated for 24 hours following administration of the study drug. The primary endpoint was occurrence of migraine-like attacks with or without aura in the 24-hour observation period.

RESULTS:

Thirteen participants developed migraine-like attacks on the active day only (P = 0.0098), and four participants developed aura on the active day only (P = 0.68). The median time to onset of migraine-like headache was three hours, and the median time to onset of aura was 27.5 minutes. CONCLUSION/

INTERPRETATION:

Our findings affirm the potent migraine-inducing effect of levcromakalim. We observed a lower induction-rate of migraine aura than previously reported. Further studies are warranted to identify predictors of migraine aura following levcromakalim. CLINICALTRIALS.GOV IDENTIFIER NCT04905654.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Enxaqueca com Aura / Epilepsia / Transtornos de Enxaqueca Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Enxaqueca com Aura / Epilepsia / Transtornos de Enxaqueca Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article